How Many Doses in a CJC-1295 No DAC Vial? (Exact Counts)
Most researchers assume one vial of CJC-1295 no DAC equals one research cycle. That's wrong. A standard 2mg lyophilised vial yields 8–20 discrete doses depending on your protocol's target dose per administration. And most research programs waste peptide by reconstituting incorrectly or storing improperly after the first draw. The difference between 8 usable doses and 20 comes down to reconstitution volume, target dose precision, and understanding sterility limits after reconstitution.
Our team has guided researchers through peptide protocol design across hundreds of lab setups. The gap between doing this right and wasting expensive peptides comes down to three things most standard guides never mention: understanding micrograms-to-millilitres conversion, preventing contamination on multi-dose draws, and knowing when reconstituted peptide degrades beyond research viability.
How many doses are in a CJC-1295 no DAC vial?
A 2mg vial of CJC-1295 no DAC yields 8–20 doses depending on protocol design. Reconstituting with 2mL bacteriostatic water produces 1000mcg/mL concentration. A 100mcg dose requires 0.1mL per administration (20 doses per vial), while a 250mcg dose requires 0.25mL (8 doses per vial). Actual yield depends on target dose, draw accuracy, and sterility maintenance across multiple punctures.
The number of doses in a vial of CJC-1295 no DAC isn't fixed. It's entirely protocol-dependent. Many researchers calculate doses based on total peptide mass without accounting for draw loss, dead volume in reconstitution, or the 28-day bacteriostatic water stability limit that caps multi-dose use regardless of remaining peptide. This article covers exact dose calculations by reconstitution volume, how draw technique affects usable yield, and what preparation mistakes negate multi-dose viability entirely.
CJC-1295 No DAC Vial Sizes and Standard Reconstitution Math
CJC-1295 no DAC is supplied as lyophilised powder in 2mg, 5mg, or 10mg vials. Though 2mg is the most common research-grade format. The peptide remains stable indefinitely at −20°C in lyophilised form, but once reconstituted with bacteriostatic water, the clock starts: 28 days maximum refrigerated storage at 2–8°C before peptide degradation and bacterial contamination risk outweigh continued use.
Reconstitution volume determines concentration, which directly controls dose count. Standard practice: add 2mL bacteriostatic water to a 2mg vial, producing 1000mcg/mL (1mg/mL). At this concentration, every 0.1mL drawn contains 100mcg peptide. If your protocol calls for 100mcg per dose, one vial yields 20 doses. If your protocol specifies 250mcg per dose, the same vial yields 8 doses. The peptide mass doesn't change. Only the volume per administration.
Dead volume. The small amount of liquid left in the vial after the final practical draw. Reduces theoretical yield by 5–10%. A 2mL reconstitution typically leaves 0.1–0.15mL undrawable liquid clinging to vial walls, reducing the 20-dose theoretical maximum to 18–19 usable doses in practice. Researchers using insulin syringes with removable needles can minimise this loss; those using fixed-needle syringes lose slightly more.
Our experience shows that researchers who plan multi-dose protocols around 28-day sterility windows rather than total peptide content avoid the most common error: assuming a 2mg vial 'should' last until the peptide is gone, when in reality bacteriostatic water's antimicrobial efficacy expires four weeks post-reconstitution regardless of remaining peptide mass.
Dose Calculation by Target Protocol Dosage
CJC-1295 no DAC research protocols typically dose between 100mcg and 500mcg per administration, with 200–250mcg being the most cited range in growth hormone research models. The number of doses you extract from a single vial depends entirely on where your protocol falls in this range.
For a 2mg vial reconstituted with 2mL bacteriostatic water (1000mcg/mL concentration):
100mcg per dose: 0.1mL per administration = 20 doses per vial (theoretical max 19 after dead volume)
200mcg per dose: 0.2mL per administration = 10 doses per vial (practical yield 9–10)
250mcg per dose: 0.25mL per administration = 8 doses per vial (practical yield 7–8)
500mcg per dose: 0.5mL per administration = 4 doses per vial (practical yield 4)
If you reconstitute with a different volume, the concentration changes proportionally. Adding 1mL bacteriostatic water to a 2mg vial produces 2000mcg/mL. Doubling the concentration means half the draw volume per dose, but doesn't change total dose count. The advantage of higher concentration is reduced injection volume for models sensitive to subcutaneous fluid load; the disadvantage is smaller margins for measurement error.
Researchers using 5mg or 10mg vials scale proportionally. A 5mg vial reconstituted with 2mL yields 2500mcg/mL. A 250mcg dose requires only 0.1mL, extending the same vial to 20 doses. Larger vials are cost-effective for long-term protocols but introduce sterility risk: more punctures over 28 days increase contamination probability with each needle entry.
We've found that calculating doses in micrograms first, then converting to millilitres based on your specific reconstitution concentration, eliminates the most common dosing errors. Write your target dose in mcg, divide by your vial concentration in mcg/mL, and the result is your draw volume in mL. This sequence prevents the backwards math that leads to 10× dosing errors.
Reconstitution Volume, Concentration, and Multi-Dose Sterility
Bacteriostatic water contains 0.9% benzyl alcohol as a bacteriostatic agent, inhibiting bacterial growth for up to 28 days after the vial is first punctured. Beyond 28 days, even refrigerated storage at 2–8°C cannot guarantee sterility. The preservative's efficacy degrades, and repeated needle punctures introduce contamination risk that compounds with each draw.
This 28-day limit is the true cap on how many doses you can extract from a vial of CJC-1295 no DAC, not the peptide mass. If your protocol administers 200mcg three times per week, you'll use 6 doses over 14 days. Well within the sterility window. If your protocol administers 100mcg once per week, you theoretically have 20 doses available, but the 28-day window allows only 4 administrations before the vial must be discarded.
Contamination risk scales with puncture count. Every needle entry. Even with alcohol swab sterilisation. Introduces potential bacterial vectors. Research-grade practice: use a fresh needle for every draw, never reinsert a used needle into the vial, and discard any vial showing visible particulate matter or cloudiness regardless of remaining peptide content.
Refrigeration at 2–8°C is non-negotiable once reconstituted. Temperature excursions above 8°C. Even brief ones. Denature the peptide's tertiary structure irreversibly. A vial left at room temperature for two hours isn't 'slightly less effective'; it's structurally compromised in ways that neither visual inspection nor home testing can detect. If cold chain integrity is uncertain, discard the vial.
We mean this sincerely: the 28-day bacteriostatic limit is not a suggestion. Extending use beyond four weeks to 'finish the vial' introduces infection risk that no research model justifies. Calculate your doses around the sterility window first, peptide content second.
CJC-1295 No DAC vs DAC: Dose Count and Frequency Implications
CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6–8 days, allowing once- or twice-weekly dosing. CJC-1295 no DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple administrations per week to maintain elevated growth hormone levels. Typically 2–3 times weekly in research protocols.
This half-life difference directly affects how many doses a single vial supports across a research timeline. A 2mg vial of CJC-1295 with DAC dosed at 2000mcg once weekly yields one dose per vial. An entire vial per administration. The same 2mg vial of CJC-1295 no DAC dosed at 200mcg three times weekly yields 10 doses, covering just over three weeks of a protocol.
The 'no DAC' variant is preferred in pulsatile growth hormone research because its short half-life mimics natural GH secretion patterns. Peak and trough rather than sustained elevation. The trade-off is dosing frequency: where one vial of the DAC variant covers one week, one vial of the no-DAC variant at equivalent weekly peptide load (600mcg total per week vs 2000mcg once-weekly) covers multiple weeks but requires more frequent administration.
Cost per protocol cycle favours no-DAC for this reason. A 12-week research model using CJC-1295 with DAC at 2mg weekly requires 12 vials. The same model using CJC-1295 no DAC at 200mcg three times weekly (600mcg weekly total) requires approximately 4 vials. Dose count per vial matters less than total peptide consumption across the full protocol timeline.
CJC-1295 No DAC Vial Dose Comparison
| Vial Size | Reconstitution Volume | Concentration (mcg/mL) | Dose per Administration | Theoretical Doses per Vial | Practical Doses (accounting for dead volume) | 28-Day Sterility Window Limit ||—|—|—|—|—|—|| 2mg | 2mL | 1000 | 100mcg (0.1mL) | 20 | 18–19 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly || 2mg | 2mL | 1000 | 200mcg (0.2mL) | 10 | 9–10 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly || 2mg | 2mL | 1000 | 250mcg (0.25mL) | 8 | 7–8 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly || 5mg | 2mL | 2500 | 250mcg (0.1mL) | 20 | 18–19 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly || 5mg | 5mL | 1000 | 200mcg (0.2mL) | 25 | 23–24 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly || 10mg | 2mL | 5000 | 500mcg (0.1mL) | 20 | 18–19 | 4 doses if dosed weekly; 12 doses if dosed 3× weekly |
Key Takeaways
A 2mg vial of CJC-1295 no DAC reconstituted with 2mL bacteriostatic water yields 8–20 doses depending on target dose per administration. 100mcg protocols extract 18–19 usable doses, while 250mcg protocols extract 7–8 doses.
Bacteriostatic water maintains sterility for a maximum of 28 days post-reconstitution, capping multi-dose use regardless of remaining peptide content. A vial dosed once weekly reaches the sterility limit after 4 administrations even if peptide remains.
Dead volume (0.1–0.15mL undrawable liquid) reduces theoretical dose count by 5–10% in practice, meaning a 20-dose calculation yields 18–19 actual draws with standard insulin syringes.
CJC-1295 no DAC's 30-minute half-life requires 2–3 administrations per week in most protocols, while the DAC variant's 6–8 day half-life allows once-weekly dosing. This frequency difference determines vial consumption rate more than dose count per vial.
Reconstituted peptide must be stored at 2–8°C continuously. Any temperature excursion above 8°C causes irreversible protein denaturation that neither appearance nor home potency testing can detect.
What If: CJC-1295 No DAC Dosing Scenarios
What If I Reconstitute with Less Water to Get More Doses?
Reducing reconstitution volume increases concentration but doesn't increase total doses. You're drawing smaller volumes per dose, but the peptide mass per vial remains fixed. Adding 1mL bacteriostatic water to a 2mg vial creates 2000mcg/mL concentration instead of 1000mcg/mL. A 200mcg dose now requires 0.1mL instead of 0.2mL, but you still get 10 doses total. The advantage is reduced injection volume for subcutaneous administration; the disadvantage is tighter measurement tolerances and higher risk of dosing error with smaller draw volumes.
What If I Store Reconstituted CJC-1295 No DAC Beyond 28 Days?
Bacteriostatic water's antimicrobial preservative (0.9% benzyl alcohol) degrades beyond 28 days, and repeated needle punctures introduce cumulative contamination risk that refrigeration alone cannot mitigate. Using a vial beyond the four-week window exposes research models to bacterial contamination that can cause injection site infections or systemic adverse events. If peptide remains after 28 days, it must be discarded. Extending use to 'finish the vial' is not worth the sterility risk.
What If My Vial Shows Cloudiness or Particulates After Reconstitution?
Discard it immediately. CJC-1295 no DAC reconstituted properly appears as a clear, colourless solution. Any cloudiness, discolouration, or visible particulate matter indicates contamination, improper reconstitution, or peptide aggregation. This is not salvageable through filtration or re-refrigeration. Particulates can indicate bacterial growth, protein precipitation, or foreign matter introduced during reconstitution, all of which compromise research integrity and model safety.
What If I Accidentally Left My Reconstituted Vial at Room Temperature Overnight?
The peptide is compromised and should be discarded. CJC-1295 no DAC in solution degrades rapidly above 8°C. An overnight temperature excursion (8–12 hours at 20–25°C) denatures the peptide's tertiary structure irreversibly. The solution may still appear clear and normal, but biological activity is significantly reduced or eliminated. Temperature-abused peptide cannot be 'restored' through re-refrigeration; the structural damage is permanent.
The Unvarnished Truth About Multi-Dose Peptide Vials
Here's the honest answer: most researchers over-estimate how many usable doses they'll extract from a multi-dose vial because they calculate based on peptide content without accounting for sterility windows and contamination risk. A 2mg vial reconstituted at 100mcg per dose theoretically yields 20 administrations. But if you're dosing once weekly, the 28-day bacteriostatic limit caps you at 4 uses, wasting 80% of the peptide. The math looks efficient on paper; the sterility reality forces waste.
The bottom line: vial size should match protocol frequency, not just total peptide need. If your research model administers CJC-1295 no DAC three times per week, a 2mg vial at 200mcg per dose covers three weeks exactly and respects the 28-day window. If you're dosing once weekly at the same per-dose amount, you need smaller vials or you accept discarding unused peptide. There's no workaround that maintains research-grade sterility standards.
Our experience working with research teams across peptide protocols shows the same pattern every time: the researchers who plan vial purchases around administration frequency rather than 'cost per milligram' avoid both waste and contamination risk. Buy the vial size your dosing schedule can exhaust within four weeks, even if the per-milligram cost is slightly higher.
CJC-1295 no DAC is one of the most studied growth hormone secretagogues in metabolic and performance research. Its short half-life and pulsatile GH release pattern make it particularly valuable for models examining natural GH dynamics. But that same short half-life demands frequent dosing, which makes multi-dose vial management critical. Get the reconstitution math right, respect the 28-day sterility cap, and dose count planning becomes straightforward. Ignore either constraint and you're either wasting peptide or risking contaminated administrations.
Researchers exploring CJC-1295 no DAC alongside other peptide compounds will find similar dose-per-vial calculation principles apply across our catalogue. Precise reconstitution, sterility-window awareness, and protocol-matched vial sizing matter as much as peptide purity itself. For labs working with pulsatile GH models, pairing CJC-1295 no DAC with a GHRP like GHRP-2 or Hexarelin creates synergistic GH response. And the same multi-dose math applies to those vials as well. You can explore high-purity research-grade peptides across multiple compound classes through Real Peptides' full peptide collection.
If the 28-day sterility limit creates unavoidable waste in your protocol design, consider whether adjusting dose frequency or switching to single-use vials reduces total cost despite higher per-milligram pricing. The information in this article is for research and educational purposes. Vial sizing, reconstitution volume, and dosing decisions should be made in consultation with experienced research personnel and institutional biosafety protocols.
Frequently Asked Questions
A 2mg vial yields 8–20 doses depending on your target dose per administration. Reconstituting with 2mL bacteriostatic water produces 1000mcg/mL concentration — a 100mcg dose requires 0.1mL per draw (20 doses), a 200mcg dose requires 0.2mL (10 doses), and a 250mcg dose requires 0.25mL (8 doses). Practical yield is 5–10% lower due to dead volume remaining in the vial after the final draw.
Reconstituted CJC-1295 no DAC remains sterile for a maximum of 28 days when stored at 2–8°C, regardless of how much peptide remains in the vial. Bacteriostatic water’s antimicrobial preservative (0.9% benzyl alcohol) degrades beyond four weeks, and repeated needle punctures introduce cumulative contamination risk. Any vial used beyond 28 days post-reconstitution should be discarded, even if peptide content remains.
No — reducing reconstitution volume increases concentration but does not increase total dose count. A 2mg vial contains 2000mcg of peptide regardless of how much water you add. Adding 1mL instead of 2mL doubles the concentration (2000mcg/mL vs 1000mcg/mL), so you draw half the volume per dose, but the total number of doses remains the same. Lower reconstitution volumes reduce injection volume per administration but increase measurement precision requirements.
CJC-1295 with DAC has a half-life of 6–8 days and is typically dosed at 2000mcg once weekly, meaning one 2mg vial equals one dose. CJC-1295 no DAC has a 30-minute half-life and is dosed at 100–250mcg multiple times per week, so one 2mg vial yields 8–20 doses depending on protocol. The no-DAC variant supports more administrations per vial but requires more frequent dosing to maintain elevated GH levels.
Divide your target dose in micrograms by your vial’s concentration in micrograms per millilitre — the result is your draw volume in millilitres. For example, if you reconstituted a 2mg vial with 2mL water (1000mcg/mL concentration) and want a 200mcg dose: 200mcg ÷ 1000mcg/mL = 0.2mL per administration. Always calculate in micrograms first, then convert to millilitres based on your specific reconstitution concentration to avoid 10× dosing errors.
Discard it immediately. Properly reconstituted CJC-1295 no DAC should be clear and colourless — cloudiness, particulates, or discolouration indicate contamination, improper mixing, or peptide aggregation. Do not attempt to filter, re-refrigerate, or use a cloudy solution. Particulate matter can signal bacterial growth or protein precipitation, both of which compromise research integrity and model safety.
No — refrigeration at 2–8°C is required to maintain peptide stability and slow bacterial growth, but it does not extend bacteriostatic water’s 28-day preservative efficacy. Even under perfect refrigeration, the benzyl alcohol preservative degrades beyond four weeks, and cumulative needle punctures introduce contamination vectors that cold storage cannot eliminate. The 28-day cap applies regardless of storage conditions.
Approximately 0.1–0.15mL of reconstituted solution remains undrawable in a standard vial due to liquid clinging to vial walls and the needle hub’s dead space. For a 2mL reconstitution (1000mcg/mL), this represents 100–150mcg of peptide — roughly 5–10% of total content. Using insulin syringes with removable needles minimises this loss compared to fixed-needle syringes, but some dead volume is unavoidable in multi-dose vial formats.
Yes, but sterility limits determine maximum use duration, not peptide content. If you dose 200mcg once weekly, a 2mg vial (10 total doses at that amount) can only support 4 administrations within the 28-day bacteriostatic window — 6 doses’ worth of peptide must be discarded. If you dose 200mcg twice weekly, the same vial supports 8 administrations over four weeks, using nearly the full peptide content before the sterility cap.
Injecting air creates positive pressure inside the vial, which can force liquid back through the needle during withdrawal, potentially introducing contaminants from the needle exterior into the vial. It also creates bubbles in the drawn solution, reducing dose accuracy. Best practice: draw back an equivalent volume of air into your syringe before inserting the needle, inject that air into the vial to equalise pressure, then draw your dose without additional air injection.
No — visual clarity does not confirm sterility or peptide integrity. Bacterial contamination can be present without visible cloudiness, and peptide degradation occurs over time even under refrigeration. The 28-day bacteriostatic limit exists because preservative efficacy and cumulative contamination risk both increase beyond that threshold, regardless of how the solution appears. Research-grade safety protocols require discarding any reconstituted vial after four weeks, even if unused peptide remains.